IsoTherapeutics Group is a radiopharmaceutical company that provides research and development services, including animal studies and early stage manufacturing for
the purpose of aiding customers and collaborators in the development of radionuclide-based drug and device products. Current collaborators include Molecular Imaging, PerkinElmer, MD Anderson
Cancer Center, University of Missouri-Columbia, Excel Diagnostics and Valco Instruments. The Company scientists, while formerly employed at The Dow Chemical Company, developed the commercial
products QUADRAMET® and Iotrex®.
AMI has partnered with IsoTherapeutics Group, LLC of Angleton, TX on the manufacturing and preclinical development of Y-90 based brachytherapy. The first project
between AMIC and IsoTherapeutics focuses on AMIC’s Y-90 RadioGel™ device. IsoTherapeutics is developing and executing studies, under AMI guidance, in the manner the FDA has requested, with the
end goal of FDA clearance for the Y-90 RadioGel™ device.
“We are pleased to offer our services to AMI and look forward to a long and outstanding collaboration that will have a significant, positive impact on the
commercialization efforts of the AMIC Y-90 brachytherapy products,” stated R. Keith Frank, Ph.D., President and CEO of IsoTherapeutics Group.